Does Cosentyx Reduce Vaccine Response?
Yes, Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, impairs immune responses to certain vaccines. Clinical data show reduced antibody production after immunization while on treatment.[1]
How Does It Affect Specific Vaccines?
- Live vaccines: Contraindicated due to infection risk from immunosuppression. Avoid during therapy and for 4-6 weeks after stopping.[1]
- Non-live vaccines: Responses are diminished. In trials, patients on Cosentyx produced 40-60% lower anti-pneumococcal antibodies after Pneumovax 23 compared to placebo. Tetanus toxoid responses dropped by about 50%.[1][2]
- COVID-19 vaccines: Real-world studies report 20-30% lower seroconversion rates (antibody positivity) post-mRNA vaccination in Cosentyx users versus healthy controls, though most still achieve protective levels.[3]
Evidence from Clinical Trials and Studies
Phase 3 trials (e.g., FUTURE, MEASURE programs) measured vaccine responses pre- and post-treatment. Secukinumab specifically blunts T-cell dependent responses via IL-17 blockade, without broadly depleting B-cells like anti-TNF drugs.[1][2] A 2023 meta-analysis confirmed consistent attenuation across IL-17 inhibitors.[4]
What Happens with Common Vaccines Like Flu or Shingles?
Influenza vaccine: Antibody titers are lower (e.g., 30% reduced hemagglutination inhibition), but breakthrough protection occurs in most.[1] Shingrix (recombinant zoster): Pre-treatment vaccination is recommended; response is adequate if given before starting Cosentyx, but impaired during therapy.[1][5]
Recommendations for Patients on Cosentyx
Vaccinate before starting therapy if possible. For non-live vaccines during treatment, experts advise proceeding but monitoring titers in high-risk cases (e.g., elderly). Revaccination post-discontinuation restores normal response within weeks.[1][6] Consult prescribing info and immunologist for timing.
How Does Cosentyx Compare to Other Biologics?
Less impact than anti-TNFs (e.g., Humira), which suppress 70-90% of responses, but similar to other IL-17/IL-23 inhibitors (e.g., Tremfya).[2][4] JAK inhibitors (e.g., Xeljanz) show comparable or greater attenuation.
Sources
[1] Cosentyx Prescribing Information (Novartis)
[2] Clinical Trial Data: FUTURE 2 Vaccine Substudy (PubMed)
[3] COVID-19 Response in IL-17 Inhibitors (RMD Open, 2022)
[4] Meta-Analysis of Biologics and Vaccines (Lancet Rheumatology, 2023)
[5] Shingrix in Immunosuppressed Patients (CDC/ACIP Guidance)
[6] EULAR Vaccine Recommendations for Rheumatic Diseases (2023)